ARTICLE | Clinical News
Prurisol: Ph IIb started
November 2, 2016 11:05 PM UTC
Cellceutix began a double-blind, placebo-controlled, U.S. Phase IIb trial to evaluate 150 and 200 mg oral Prurisol twice daily for 12 weeks in about 189 patients. The company is developing Prurisol un...
BCIQ Company Profiles